Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-31R&Dtruetrue12023-01-01false1The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 04988521 2023-01-01 2023-12-31 04988521 2022-01-01 2022-12-31 04988521 2023-12-31 04988521 2022-12-31 04988521 c:Director1 2023-01-01 2023-12-31 04988521 d:CurrentFinancialInstruments 2023-12-31 04988521 d:CurrentFinancialInstruments 2022-12-31 04988521 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 04988521 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 04988521 d:ShareCapital 2023-12-31 04988521 d:ShareCapital 2022-12-31 04988521 d:RetainedEarningsAccumulatedLosses 2023-12-31 04988521 d:RetainedEarningsAccumulatedLosses 2022-12-31 04988521 c:OrdinaryShareClass1 2023-01-01 2023-12-31 04988521 c:OrdinaryShareClass1 2023-12-31 04988521 c:OrdinaryShareClass1 2022-12-31 04988521 c:FRS102 2023-01-01 2023-12-31 04988521 c:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 04988521 c:FullAccounts 2023-01-01 2023-12-31 04988521 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 04988521 e:PoundSterling 2023-01-01 2023-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 04988521









MOLECULAR SYNTHETICS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2023

 
MOLECULAR SYNTHETICS LIMITED
REGISTERED NUMBER: 04988521

BALANCE SHEET
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

  

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 4 
100
100

Creditors: amounts falling due within one year
 5 
(103,235)
(101,141)

NET CURRENT LIABILITIES
  
 
 
(103,135)
 
 
(101,041)

NET LIABILITIES
  
(103,135)
(101,041)


CAPITAL AND RESERVES
  

Called up share capital 
 6 
1,000
1,000

Profit and loss account
  
(104,135)
(102,041)

  
(103,135)
(101,041)


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Dr M Bacon
Director

Date: 27 August 2024

The notes on pages 2 to 3 form part of these financial statements.

Page 1

 
MOLECULAR SYNTHETICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


GENERAL INFORMATION

Molecular Synthetics Limited is a private company limited by shares and incorporated in England and
Wales. The address of the registered office is Salisbury House, Station Road, Cambridge, CB1 2LA. The
company has no permanent trading premises.
The Company's functional and presentational currency is GBP and the figures are rounded to the nearest
pound. 

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

GOING CONCERN

In common with other development stage companies, the company has incurred a loss for the year
and has net liabilities at the year end. The company has received assurances from the directors that
they will continue to provide ongoing financial support to the company, and consequently the
accounts are prepared on the going concern basis.

 
2.3

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.4

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


EMPLOYEES

The average monthly number of employees, including the directors, during the year was as follows:


        2023
        2022
            No.
            No.







Staff
1
1

Page 2

 
MOLECULAR SYNTHETICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

4.


DEBTORS

2023
2022
£
£

Called up share capital not paid
100
100

100
100



5.


CREDITORS: AMOUBNTS FALLING DUE WITHIN ONE YEAR

2023
2022
£
£

Trade creditors
3,143
3,143

Other creditors
98,682
96,648

Accruals and deferred income
1,410
1,350

103,235
101,141



6.


SHARE CAPITAL

2023
2022
£
£
ALLOTED, CALLED UP AND FULLY PAID



900 (2022 - 900) Ordinary shares of £1 each shares of £1.00 each
900
900

ALLOTTED CALLED UP AND PARTLY PAID



100 (2022 - 100) Ordinary shares of £1 each shares of £1.00 each
100
100


 
Page 3